VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection

Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased canc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Räsänen, Markus, Degerman, Joni, Nissinen, Tuuli A., Miinalainen, Ilkka, Kerkelä, Risto, Siltanen, Antti, Backman, Janne T., Mervaala, Eero, Hulmi, Juha J., Kivelä, Riikka, Alitalo, Kari
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2016
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5135329/
https://ncbi.nlm.nih.gov/pubmed/27799559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1616168113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars